Abbott begins VOYAGER trial of investigational Encantor TAVI system

Abbott has initiated the VOYAGER CE clinical trial evaluating its investigational Encantor balloon-expandable transcatheter aortic valve implantation system in patients with symptomatic severe aortic stenosis.

The prospective, single-arm pre-market study will enrol up to 300 patients across Europe and Australia.

The first patient was enrolled at Macquarie University in Sydney, Australia.

Results from VOYAGER CE are intended to support future regulatory submissions for the Encantor system in Europe and Australia.

Encantor combines a balloon-expandable transcatheter heart valve with software-guided deployment technology designed to help physicians tailor valve expansion to an individual patient’s anatomy.

The system is being developed for patients with severe aortic stenosis caused by calcium accumulation and narrowing of the aortic valve.

During the procedure, the replacement valve is mounted on a deflated balloon and delivered through a catheter inserted through an artery in the groin.

Once positioned inside the diseased aortic valve, the balloon is expanded to deploy the replacement valve.

Abbott’s software-guided system is intended to help customise expansion during deployment and support precise positioning and valve performance.

Didier Tchétché, MD, Director of the Structural Heart Disease Department at Clinique Pasteur in Toulouse and co-principal investigator of VOYAGER CE, said the technology is designed to give physicians greater control when adapting TAVI procedures to individual patients.

Abbott developed Encantor using experience from its existing Navitor self-expanding TAVI platform.

The company said the balloon-expandable system is intended to complement Navitor and broaden the range of transcatheter valve technologies available within its structural heart portfolio.

Initiation of VOYAGER CE follows an early feasibility study evaluating Encantor.

Six-month findings assessing safety, haemodynamic performance and functional outcomes from that study are scheduled to be presented at PCR London Valves 2026.

Abbott said the early feasibility findings supported progression into the VOYAGER CE programme.

Sandra Lesenfants, Senior Vice President of Abbott’s structural heart business, said development of Encantor is intended to provide physicians with an additional valve platform focused on controlled deployment and procedural ease of use.

The Encantor system remains investigational and is not approved for clinical use in any country.

Abbott also plans to begin a pivotal U.S. study of the system in the coming months.



Related Topics and Keywords

, , , , , , , , , , , , , , , , , , ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy